Identifying an appropriate endpoint for cryoablation in children with atrioventricular nodal reentrant tachycardia: Is residual slow pathway conduction associated with recurrence?


Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
02 2022
Historique:
received: 13 12 2020
revised: 14 09 2021
accepted: 24 09 2021
pubmed: 4 10 2021
medline: 15 3 2022
entrez: 3 10 2021
Statut: ppublish

Résumé

Cryoablation is increasingly used to treat atrioventricular nodal reentrant tachycardia (AVNRT) due to its safety profile. However, cryoablation may have higher recurrence than radiofrequency ablation (RFA), and the optimal procedural endpoint remains undefined. The purpose of this study was to identify the association of cryoablation procedural endpoints with postprocedural AVNRT recurrence. We performed a single-center, retrospective analysis of pediatric patients following successful first-time cryoablation for AVNRT between January 1, 2011, and December 31, 2019. Preablation inducibility of AVNRT was recorded. Procedural endpoints, including slow pathway (SP) conduction (presence of jump or echo beats) with and without isoproterenol, were identified. Recurrence was established from clinical notes and/or direct patient contact. Of 256 patients, 147 (57%) were assessed on isoproterenol precryoablation, and 171 (47%) were assessed on isoproterenol postcryoablation. Mean cryolesion time was 2586 ± 1434 seconds. Following ablation, 104 (41%) had some evidence of residual SP conduction. With median follow-up time of 1.9 [0.7-3.7] years, recurrence occurred in 14 patients (5%). Complete elimination of SP conduction (with and without isoproterenol) had a hazard ratio for recurrence of 1.26 (95% confidence interval [CI] 0.42-3.8; P = .68) on univariate analysis and 1.39 (95% CI 0.36-5.4; P = .63) on multivariate analysis (including demographics, ablation time, 8-mm cryocatheter, and baseline inducibility). The observed AVNRT recurrence rate after cryoablation was comparable to that of RFA. The presence of residual SP conduction was not associated with recurrence. This suggests that jump or single echo beat may be an acceptable endpoint in AVNRT cryoablation.

Sections du résumé

BACKGROUND
Cryoablation is increasingly used to treat atrioventricular nodal reentrant tachycardia (AVNRT) due to its safety profile. However, cryoablation may have higher recurrence than radiofrequency ablation (RFA), and the optimal procedural endpoint remains undefined.
OBJECTIVE
The purpose of this study was to identify the association of cryoablation procedural endpoints with postprocedural AVNRT recurrence.
METHODS
We performed a single-center, retrospective analysis of pediatric patients following successful first-time cryoablation for AVNRT between January 1, 2011, and December 31, 2019. Preablation inducibility of AVNRT was recorded. Procedural endpoints, including slow pathway (SP) conduction (presence of jump or echo beats) with and without isoproterenol, were identified. Recurrence was established from clinical notes and/or direct patient contact.
RESULTS
Of 256 patients, 147 (57%) were assessed on isoproterenol precryoablation, and 171 (47%) were assessed on isoproterenol postcryoablation. Mean cryolesion time was 2586 ± 1434 seconds. Following ablation, 104 (41%) had some evidence of residual SP conduction. With median follow-up time of 1.9 [0.7-3.7] years, recurrence occurred in 14 patients (5%). Complete elimination of SP conduction (with and without isoproterenol) had a hazard ratio for recurrence of 1.26 (95% confidence interval [CI] 0.42-3.8; P = .68) on univariate analysis and 1.39 (95% CI 0.36-5.4; P = .63) on multivariate analysis (including demographics, ablation time, 8-mm cryocatheter, and baseline inducibility).
CONCLUSION
The observed AVNRT recurrence rate after cryoablation was comparable to that of RFA. The presence of residual SP conduction was not associated with recurrence. This suggests that jump or single echo beat may be an acceptable endpoint in AVNRT cryoablation.

Identifiants

pubmed: 34601128
pii: S1547-5271(21)02207-4
doi: 10.1016/j.hrthm.2021.09.031
pii:
doi:

Substances chimiques

Isoproterenol L628TT009W

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

262-269

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Nina Zook (N)

Department of Pediatrics, Lucile Packard Children's Hospital, Stanford, Palo Alto, California. Electronic address: ninazook@stanford.edu.

Kimberly DeBruler (K)

Department of Medical Education, Stanford Medical School, Stanford University, Palo Alto, California.

Scott Ceresnak (S)

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.

Kara Motonaga (K)

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.

William Goodyer (W)

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.

Anthony Trela (A)

Department of Cardiology, Lucile Packard Children's Hospital, Palo Alto, California.

Anne Dubin (A)

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.

Henry Chubb (H)

Division of Pediatric Cardiology, Department of Pediatrics, Stanford University, Palo Alto, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH